GBCA

(redirected from Gadolinium-Based Contrast Agent)
AcronymDefinition
GBCAGreen Building Council of Australia
GBCAGadolinium-Based Contrast Agent
GBCAGeneral Building Contractors Association
GBCAGreater Baltimore Cultural Alliance (Maryland)
GBCAGalveston Bay Cruising Association
GBCAGreater Boston Concierge Association
GBCAGrassland Bird Conservation Area
GBCAGrizzly Bear Conservation Area
GBCAGraphics-Based Control Architecture
GBCAGreater Boston Cable Advertising
GBCAGranite Bay Community Association (Granite Bay, CA)
GBCAGerman Brown Coal Association
GBCAGreat Band of Christmas Aid
References in periodicals archive ?
The first commercial use of a gadolinium-based contrast agent in the UK was in 1988 and they have been part of clinical routine ever since.
Gadolinium-based contrast agents, when given to patients with renal disease, have been associated with a rare, potentially fatal, scleroderma-like skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy.
According to a study published in August 2006 in the Journal of the American Society of Nephrology, 13 patients with severe renal disease developed NSF between two and 75 days after receiving Omniscan, a gadolinium-based contrast agent manufactured by GE Healthcare.
It recommends that these agents be used only if absolutely necessary with prompt dialysis following the test in order to remove the circulating gadolinium-based contrast agent (USFDA, 2006).
It is usually done with gadolinium-based contrast agent, with the radiologist reading an image without contrast agent and then a series of images after the contrast agent is injected to watch the uptake and the rate of the washout of the contrast agent, all of which may take experience.
Berlex Imaging of Montville, N.J., which manufactures the gadolinium-based contrast agent Magnevist, said that as of Dec.
Matsuda et al., "Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy," Radiology, vol.
15 March 2011 - Bayer HealthCare Pharmaceuticals Inc said Monday that the US Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).
When patients with renal disease must receive a gadolinium-based contrast agent, prompt dialysis following the MRI or MRA should be considered, the FDA statement said.
These are performed as multiple breath-hold sequences before and at timed intervals after IV bolus injection of a gadolinium-based contrast agent. Reproducible diaphragmatic excursion during breath-holds allows for more accurate computer-processed image subtraction and better visual appreciation of the degree of lesion enhancement.